Beyond weight reduction, the highest retatrutide dose produced clinically meaningful improvements in several cardiometabolic risk markers, including average reductions of 37.0% in triglycerides, 16.5% in non-HDL cholesterol, 9.3 mmHg in systolic blood pressure, 19.0 cm in waist circumference, and 51.2% in high-sensitivity C-reactive protein (hsCRP), a marker of systemic inflammation
Blood samples were collected from the tail vein at 0, 30, 60, 90, and 120 min after treatment
In March 2026, a Foundayo is notable not only for its oral formulation but also for being among the first medications approved under the FDAs new Additionally, unlike other oral GLP-1s, it does not require the fasting and water restrictions associated with oral semaglutide, potentially making it more accessible
VIVITROL (naltrexone for extended-release injectable suspension) U.S
receive after-care guidance and nutrition tips